Drug intelligence / Profile preview

GB-7624

Development stage: Phase 1
Lead developer: Generate Biomedicines
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

**Description:** GB-7624 is an investigational monoclonal antibody developed by Generate Biomedicines. It targets and inhibits Interleukin-13 (IL-13), a cytokine implicated in the pathophysiology of Type 2 inflammatory diseases, with its primary therapeutic indication being atopic dermatitis. The drug is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants[1][3][6]. **Mechanism of Action:** IL-13 inhibitor; specifically binds to IL-13 to block its signaling pathway[2][3][6]. **Developer:** Generate Biomedicines.

Other names: GB-7624GB7624GB 7624

Targets

IL-13 (Interleukin-13)

Beyond the preview

Go deeper on GB-7624.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-7624.

Explore the full profile